With support from Combat Casualty Care Research Program and MTEC, Cayuga Biotech, Inc. demonstrated that their lead product, a polyphosphate silica nanoparticle complex (polyP-SNP), generated thrombin 12 times faster than control, resulting in faster clotting with low potential for off-target thromboembolism. The results were recently presented at the Annual Meeting of the International Society of Thrombosis and Haemostasias (ISTH) in Bangkok, Thailand.
Nearly 2 million people globally per year die of hemorrhage, the majority of which is preventable. The top causes of preventable death by hemorrhage are non-compressible hemorrhage sites (such as internal bleeding and from penetrating injury) and delays in hemostatic control neither of which are adequately addressed by today’s current care model. Due to the nature of non-compressible hemorrhage sites, the complexity of clinical intervention is time consuming and delays in treatment often lead to patient death.
Data presented in the ISTH “New strategies for reversal and prevention of bleeding” session demonstrated faster clotting in vitro and ex vivo and acceleration of thrombin generation, which is the critical factor that determines the ability to clot quickly and effectively. As an injected drug that is inert in healthy tissue, the polyP-SNP complex travels via the bloodstream to any site of bleeding and acts to accelerate the clotting response without driving excess clotting. The activity of polyP-SNP complex is independent of FXII activation, which suggests a low potential for causing clotting in healthy tissue, a problem that has limited development for other injectable drugs to treat hemorrhage.
Cayuga anticipates enrolling their first patient in a Phase 1 study by the end of 2024. This trial is structured as a dose escalation safety study and includes endpoints for coagulation.
The research project award recipients were selected from the respondents to MTEC’s Request for Project Proposals soliciting medical technological solutions related to MTEC’s Technology Focus Areas (Solicitation #MTEC-21-06-MPAI).
About Cayuga Biotech, Inc.: Cayuga is developing novel biomimetic therapies leveraging inorganic polyphosphate, a polymer that modulates the healing response. The company has an optimized polyP-SNP complex in late preclinical development for the treatment of acute major hemorrhage, a discovery-stage novel composition for the treatment of inherited bleeding disorders, as well as a portfolio of early-stage programs focused across the healing continuum.
Further reading on Cayuga Biotech, Inc. and its advancements:
visit www.CayugaBiotech.com
